CIINBIO@EC2606A(27141.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
CIINBIO@EC2606A
27141.HK
News
View More

CICC Sticks to Their Buy Rating for Innovent Biologics (IVBXF)

CICC analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$118.30. The company’s shares closed yesterday at HK$79.50.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$123.93.

Tip Ranks·
SH
588250
-0.18%
SH
588130
0.00%
SZ
159992
-0.12%
Tip Ranks·
SH
588250
-0.18%
SH
588130
0.00%
SZ
159992
-0.12%

Goldman Sachs: INNOVENT BIO had strong product sales last year, target price 102.85 yuan, recommends buying

Goldman Sachs released a research report stating that INNOVENT BIO's product revenue in the fourth quarter of last year was approximately 3.3 billion yuan, in line with expectations, with a year-on-year growth of 60%. Product sales are expected to grow strongly by 45% to 11.9 billion yuan in 2025, surpassing 10 billion yuan for the first time. Goldman Sachs raised its earnings per share forecast for 2025 to 2027 and adjusted the target price to HKD 102.85, maintaining a "Buy" rating

AASTOCKS·
HK
01801
-0.50%
AASTOCKS·
HK
01801
-0.50%

Innovent Biologics' Q4 Revenue Surges 60%

Innovent Biologics' Q4 Revenue Surges 60%

marketscreener·
HK
01801
-0.50%
marketscreener·
HK
01801
-0.50%

Innovent Biologics Reports 45% Year-Over-Year Growth in 2025 Product Revenue

Innovent Biologics Inc. reported a 45% year-over-year growth in product revenue for 2025, totaling approximately RMB11.9 billion. In Q4 2025, product revenue reached around RMB3.3 billion, also showing significant growth. The company recognized inventory price adjustments due to the addition of six new drugs to the 2026 National Reimbursement Drug List. This financial information is based on internal records and has not been audited. The original content was published via the Hong Kong Stock Exchange.

Reuters·
SH
589720
0.00%
SH
588860
-0.43%
SH
588250
-0.18%
Reuters·
SH
589720
0.00%
SH
588860
-0.43%
SH
588250
-0.18%

Innovent receives fast track designation from FDA for IBI3003, a trispecific antibody for multiple myeloma. Jan. 26, 2026.

On January 26, 2026, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical firm based in San Francisco and Suzhou, China, specializes in the development, production, and distribution of top-tier medications. Their focus is on treating various conditions including oncologic, autoimmune, and cardiovascular diseases.

Unusual Whales·
HK
01801
-0.50%
Unusual Whales·
HK
01801
-0.50%
Posts
View More
© 2026 Longbridge｜Disclaimer